AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02924688
Drug: FF/VI (100/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Trial: NCT02924688
Drug: FF/VI (200/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Trial: NCT00648141
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily for 12 weeks
Trial: NCT00648141
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule twice daily for 12 weeks
Trial: NCT00648141
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg oral capsule twice daily for 12 weeks
Trial: NCT04462536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle only
Trial: NCT02152358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01969942
Drug: Clyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02574858
Drug: QRH-882260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
Trial: NCT01596530
Drug: Drug-AZD8931
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug for biological activity
Trial: NCT01596530
Drug: Drug-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator for biological activity comparison
Trial: NCT04899960
Drug: Clinical Pharmacist Intervention
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
Trial: NCT02570529
Drug: Albis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Trial: NCT02570529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Trial: NCT01848639
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Trial: NCT01848639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Trial: NCT00114270
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00797485
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00797485
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00797485
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02487277
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05008068
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin with PRF at site of osteotome
Trial: NCT01734707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Allicor 150 mg tablet
Trial: NCT01712217
Drug: AT13387
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSP90 inhibitor
Trial: NCT02452112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch to be placed on the site of pain
Trial: NCT00571688
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
Trial: NCT03409419
Drug: [18F] CFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
Trial: NCT04372342
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil
Trial: NCT01684475
Drug: CJH1 (CLR4001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04584853
Drug: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation
Trial: NCT02190747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01612377
Drug: Prednisolone-Dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, QD
Trial: NCT01508494
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01570478
Drug: Foster® NEXThaler® 100/6 µg/unit dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
Trial: NCT01570478
Drug: Seretide® Accuhaler® 250/50 µg/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
Trial: NCT00430963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01978509
Drug: Moderate volume prep (Moviprep)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Trial: NCT03537352
Drug: Any appropriate drug or non-drug treatment excluding surgery
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
Trial: NCT01896388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01078714
Drug: bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Trial: NCT01700985
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied twice daily for two weeks
Trial: NCT02790671
Drug: DS-8500a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 25mg tablet
Trial: NCT01788982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02180217
Drug: LCI699 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Trial: NCT00744016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning
Trial: NCT02188719
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Trial: NCT01214941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given orally placebo twice a day for 5 days prior to the study.
Trial: NCT01578785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
Trial: NCT01273389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
Trial: NCT02993913
Drug: Simmiparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simmiparib Tablets, oral administration
Trial: NCT00255099
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg tablets b.i.d. / 96 weeks
Trial: NCT00255099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets b.i.d. / 96 weeks
Trial: NCT01033487
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral inhaled formulation, single dose
Trial: NCT04465123
Drug: Spironolactone or hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours.
Trial: NCT04465123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours.
Trial: NCT04529135
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Trial: NCT02172807
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo metered dose inhaler (MDI)
Trial: NCT02172807
Drug: Placebo inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02168881
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01263093
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01915108
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
Trial: NCT02236741
Drug: Mirapexin® (Sifrol®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00120289
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
Trial: NCT02858973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00614653
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 PO Twice Daily on days with radiation.
Trial: NCT03213977
Drug: R-DA-EPOCH
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Trial: NCT03213977
Drug: R-CEOP90
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Trial: NCT02705768
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
Trial: NCT02922192
Drug: TNF-α antagonists, non-TNFs, DMARD non-biologics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
Trial: NCT00000450
Drug: Matched Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668030
Drug: Enzymatic agent
RxNorm normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymatic agent
Trial: NCT04266106
Drug: SuperBio probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule po BID for 28 days
Trial: NCT01958879
Drug: ringer without corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL Ringer solution
Trial: NCT02067741
Drug: CR1447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg, corresponding to two 4 g stick packs applications twice daily
Trial: NCT00779311
Drug: mFOLFOX6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
Trial: NCT02855450
Drug: rhNGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
Trial: NCT02855450
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
Trial: NCT02306239
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00866515
Drug: Placebo + GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match D1-6 + GW642444M 25ug single dose on D5
Trial: NCT02438215
Drug: IRX4204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
Trial: NCT02098057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Trial: NCT01645085
Drug: MCC-based 13% drug loaded tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg tablets, dosed as 2 tablets (100mg total)
Trial: NCT01645085
Drug: MCC-based 13% drug loaded tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets (150mg total)
Trial: NCT02146248
Drug: DepoProvera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable hormonal contraceptive
Trial: NCT00671814
Drug: TR-701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
Trial: NCT00671814
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
Trial: NCT01315847
Drug: [11C]MK-4232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
Trial: NCT04101760
Drug: Long-acting granulocyte colony stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
Trial: NCT03694041
Drug: SAD: APX-115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: APX-115 SAD APX-115 SAD for 1day
Trial: NCT03694041
Drug: SAD: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Placebo for 1day
Trial: NCT03694041
Drug: MAD: APX-115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: APX-115 MAD APX-115 MAD repeatedly administered.
Trial: NCT03694041
Drug: MAD: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching study drug will be repeatedly administered.
Trial: NCT03571256
Drug: TEV-50717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-, 9-, 12-, 15-, and 18 mg oral tablets
Trial: NCT03571256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEV-50717 tablets will be taken BID.
Trial: NCT00977015
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, 750/150, single dose
Trial: NCT00977015
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, 750/150, single dose
Trial: NCT00764478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo sublingual tablet, administered BID for 21 days
Trial: NCT00575094
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
Trial: NCT00245414
Drug: Pegasys®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180μg for s.c./week for 48 weeks
Trial: NCT00245414
Drug: Pegasys®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180μg for s.c./week for 24 weeks
Trial: NCT00466583
Drug: Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.